Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)

Lambert, J.; Segaert, Siegfried; Ghislain, Pierre-Dominique; Hillary, Tom; Nikkels, Arjen; Willaert, F.; Lambert, Jo; Speeckaert, Reinhart

doi:10.1111/jdv.16684

Cited by 31 publications

(48 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comorbidities could influence the treatment strategy (14). Figure 2 lists selected therapeutics for adult systemic psoriasis with comorbidities (74)(75)(76)(77). Treatment should be tailored to meet the needs of patients (Figure 2).…”

Section: Therapy For Psoriasismentioning

confidence: 99%

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Yan

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Psoriasis is a chronic multisystem inflammatory disease that affects ~0.1–1.5% of the world population. The classic cutaneous manifestation of psoriasis is scaly erythematous plaques, limited or widely distributed. Moreover, psoriasis could be associated with comorbidities like psoriatic arthritis, metabolic syndrome, diabetes, cardiovascular disease, nephropathy, bowel disease, and brain diseases. In this review, we suggest that psoriasis should be classified as cutaneous psoriasis or systemic psoriasis and propose the classification for distinction. This would help to better understand and manage psoriasis.

show abstract

Section: Therapy For Psoriasismentioning

confidence: 99%

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Yan

Chen

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Inclusion to such programmes elements specific for narrow professional groups may be beneficial. It is now a popular tendency to make specific recommendations for narrow subgroups of patients to increase its efficacy 20,21 . Our results may also be used in development of occupational skin diseases‐specific HRQoL instruments.…”

Section: Discussionmentioning

confidence: 73%

Prospective study on hand dermatitis in nurses and doctors during COVID ‐19 pandemic and its improvement by use of adopted recommendations of the European Academy of Dermatology and Venereology Task Force on Contact Dermatitis

Chernyshov

Kolodzinska

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Frequency of hand disinfection and adverse skin reactions among health care workers dramatically increased since the COVID-19 outbreak and consensus recommendations on hand hygiene were presented. The aim of the present study was to check the efficacy of the European Academy of Dermatology and Venereology (EADV) Task Force (TF) on Contact Dermatitis (CD) recommendations in a real life and to search if providing products mentioned in that recommendations may increase its efficacy. Doctors and nurses who worked with patients during COVID-19 pandemic and use hand disinfectants received adopted recommendations of the EADV TF on CD only or together with mentioned in that recommendations gel with ethanol and glycerin and emollient. Prevalence of adverse skin reactions on hand disinfectants at baseline was 80.21%. In a month significant improvement of health-related quality of life (HRQoL) and self-assessed improvement of hand skin (P < .01 for both) was reported in "products" group only. Number of participants that had no impact on their HRQoL became higher and the Dermatology Life Quality Index scores lower than in "recommendations only" group (P = .03 and P = .02, respectively). Our results showed that recommendations of the EADV TF on CD may significantly improve HRQoL and hand skin status in health care professionals but provision with products mentioned in that recommendations is crucial.

show abstract

“…However, there are no conclusive data to enunciate meaningful clinical recommendations. Although some studies suggest that TNF-α inhibitors are associated with a decrease in insulin resistance, the study by Wu et al has shown no benefit with anti-TNF-α drugs in combination with methotrexate versus methotrexate alone on HbA1C or fasting blood glucose in psoriasis patients [ 130 , 131 , 132 , 133 ]. There is no evidence to show whether one of the listed drugs is efficacious compared with another in a patient with psoriasis and fatty liver disease [ 134 ].…”

Section: Discussionmentioning

confidence: 99%

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

Psoriasis is an immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2–3% of the worldwide population. The progressive acquisitions of the inflammatory pathways involved in the development of psoriasis have led to the identification of the key molecules of the psoriatic inflammatory cascade. At the same time, psoriasis therapy has radically evolved with the introduction of target molecules able to modify the natural history of the disease, acting specifically on these inflammatory pathways. For these reasons, biologics have been demonstrated to be drugs able to change the disease’s natural history, as they reduce the inflammatory background to avoid irreversible organ damage and prevent systemic complications. However, several issues related to the use of biologics in patients with systemic comorbidities, remain open. All these data reflect the extraordinary potentiality of biologics, but also the unmet medical need to improve our knowledge on the long-term risk related to continuous use of these drugs, and their administration in special populations. This narrative review aims to highlight both the efficacy and safety profile of biologics in psoriasis, starting from pathophysiology and moving towards their clinical application.

show abstract

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)

Cited by 31 publications

References 78 publications

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction

Prospective study on hand dermatitis in nurses and doctors during COVID ‐19 pandemic and its improvement by use of adopted recommendations of the European Academy of Dermatology and Venereology Task Force on Contact Dermatitis

Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches

Contact Info

Product

Resources

About